Piddock L J, Traynor E A, Wise R
Department of Medical Microbiology, Medical School, University of Birmingham, UK.
J Antimicrob Chemother. 1989 Mar;23 Suppl C:59-64. doi: 10.1093/jac/23.suppl_c.59.
The susceptibility of 47 clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) to FCE 22101, imipenem and methicillin was determined with Iso-Sensitest media, with or without NaCl and with incubation at 30 degrees and 37 degrees C and for 24 and 48 h. All strains had a MIC 8 mg/l of methicillin under at least one of the culture conditions. The MIC90 of FCE 22101 was 1 mg/l, and that of imipenem 16 mg/l. The affinity of FCE 22101 for the penicillin-binding proteins (PBPs) of five clinical isolates of MRSA and S. aureus 13136 p-m+ was examined in envelope preparations and whole cell assay under the growth conditions listed above. PBP 2' was detected in all MRSA, and the clinical isolates had an I50 of 4 mg/l FCE 22101. These in-vitro data suggest that FCE 22101 may be active against MRSA in clinical use.
采用异感试验培养基，在添加或不添加氯化钠的情况下，于30℃和37℃孵育24小时和48小时，测定了47株耐甲氧西林金黄色葡萄球菌（MRSA）临床分离株对FCE 22101、亚胺培南和甲氧西林的敏感性。在至少一种培养条件下，所有菌株对甲氧西林的最低抑菌浓度（MIC）均为8mg/l。FCE 22101的MIC90为1mg/l，亚胺培南的MIC90为16mg/l。在上述生长条件下，通过包膜制剂和全细胞试验，检测了FCE 22101对5株MRSA临床分离株和金黄色葡萄球菌13136 p-m+的青霉素结合蛋白（PBPs）的亲和力。在所有MRSA中均检测到PBP 2'，临床分离株对FCE 22101的半数抑制浓度（I50）为4mg/l。这些体外数据表明，FCE 22101在临床应用中可能对MRSA具有活性。
